Physician profile
Stephen Keith
NPI 1457332066
$9,453.71
in general payments reported to CMS, 2019-2025
40 companies · $507 in 2025
The $507 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,663 · 2020: $1,382 · 2021: $1,089 · 2022: $1,621 · 2023: $1,699 · 2024: $1,493 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,698.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,305.34 | 2019-2025 | |
| Janssen Biotech, INC. | $1,185.40 | 2019-2025 | Stelara, Remicade, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,040.58 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Qol Medical, LLC | $534.09 | 2019-2024 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $365.92 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $317.63 | 2020-2024 | Linzess |
| Celgene Corporation | $316.65 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $302.75 | 2022-2025 | Ibsrela |
| Allergan, INC. | $289.90 | 2019-2020 | |
| Genzyme Corporation | $245.73 | 2023-2025 | |
| Intercept Pharmaceuticals, INC. | $211.99 | 2019-2023 | Ocaliva |
| Pacira Pharmaceuticals Incorporated | $195.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $180.70 | 2019-2024 | Entyvio, Gattex |
| Conmed Corporation | $177.49 | 2020-2022 | |
| Janssen Scientific Affairs, LLC | $161.73 | 2022-2023 | Stelara |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Keith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.